The aim of this work is to formulate and evaluate ethanol extract of Propolis as a vaginal suppository. The suppository was formulated using the pouring methodand cocoa butter as a base. The formulated suppositories were evaluated using physical appearance, crushing strength test, disintegration and dissolution time's tests, stability, as well as content uniformity. The visual examination showed brilliant and smooth surfaced, consistently bullet shaped, yellowish brown color and characteristic scented odor. The results of crushing strength (4.22 ± 0.92), disintegration time (7.25 ±0.17) and content uniformity (99.16 ± 1.13) were within the normal limits. The result obtained from the dissolution time test showed that the suppositories dissolved within 35 min. The results indicated that ethanol extract of propolis can be formulated into a vaginal suppository.

Tizanidine Hydrochloride, is an centrally acting myotonolytic skeletal muscle relaxant. It undergoes first pass metabolism on oral administration resulting in less bioavailability (40%).Present research work was carried out to formulate and develop transdermal patch of Tizanidine hydrochloride which will overcome the limitation of bioavailability. In the present study transdermal patches were prepared by solvent-casting method using hydrophilic polymer HPMC E-5 LV, chitosan, Moringa oleifera gum and Propylene Glycol as plasticizer. The six formulations were prepared and evaluated. Accelerated stability studies of drug containing films, were performed according to ICH guidelines. It was found that, Moringa oleifera gum has potential to modify drug release rate and posses good film former and adhesive property. The transdermal patch has shown promising drug release within 12 hr (84.36%), good stability and no irritancy.

The present study was aimed at developing a reversed phase high performance liquid chromatography (RP-HPLC) method for determination of Gefitinib (GFT) in Tissue Samples (Brain Homogenate) and hydrochlorothiazide was used as an internal standard. The separation was achieved by using C-18 column (Qualisil BDS C18, 250 mm x 4.6 mm I.D.) coupled with a guard column of silica, mobile phase was consisting of acetonitrile: water with 0.1% formic acid (50:50 v/v). The flow rate was 0.2 mL/min and the drug was detected using PDA detector at the wavelength of 254 nm. The experimental conditions, including the diluting solvent, mobile phase composition, column saturation and flow rate, were optimised to provide high-resolution and reproducible peaks. The developed method was validated in terms of linearity, recovery, precision, sensitivity (LOD and LOQ) and stability study (short and long-term stabilities, Freeze/thaw stability and post-preparative).

UV Spectrophotometric Method Development and Validation for quantitative estimation of Ondansetron Hydrochloride (HCL). U.V Spectrophotometric method have been widely employed in determination of individual components in a mixture or fixed dose combination. Our aim is to develop spectroscopic method for estimation of the Ondansetron HCL in ternary mixture by using U.V spectrophotometry. The method was validated as per ICH guidelines. The recovery studies confirmed the accuracy and precision of the method. It was successfully applied for the analysis of the drug in bulk and could be effectively used for the routine analysis.

A mixture of 3-cyano-2-metylthio-4-oxo-4H-pyrimido [1, 2-a] benzimidazole was condensed with different substituted benzothiazole in presence of catalytic amount of anhydrous potassium carbonate and N, N'- dimethyl formamide as a reaction solvent, to get corresponding 6-imino-7-oxo-benzimidazolo [2, 3-b] pyrimido [5, 6-e]pyrimido [2, 3-b][1, 3] benzothiazole and their substituted derivatives. All the products were confirmed by their IR, 1H NMR and mass spectroscopic measurements. All this compounds were screened for their antimcribial and antioxidant activity.